Emergent BioSolutions infectious news

Emergent received a multi-year grant from NIH's National Institute of Allergy and Infectious Diseases (NIAID) to develop tuberculosis (TB) vaccine candidate MVA85A. Details were not disclosed.

The vaccine is in Phase IIb testing and is being developed with Aeras (Rockville, Md.), a not-for-profit biotech developing TB vaccines, and the Oxford-Emergent Tuberculosis Consortium Ltd., a joint venture between Emergent and the University of Oxford (Oxford, U.K.). MVA85A, a recombinant modified vaccinia virus Ankara expressing Mycobacterium tuberculosis antigen 85A, has Orphan Drug designation in the EU. ...